



**22<sup>nd</sup> Asia-Pacific League of  
Associations for Rheumatology  
Virtual Congress**  
24 - 29 October 2020

## **Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations (MAXIMISE trial)**

**Xenofon Baraliakos<sup>1</sup>, Laure Gossec<sup>2</sup>, Effie Pournara<sup>3</sup>, Slawomir Jeka<sup>4</sup>, Ricardo Blanco<sup>5</sup>, Salvatore D'Angelo<sup>6</sup>, Georg Schett<sup>7</sup>, Barbara Schulz<sup>3</sup>, Michael Rissler<sup>3</sup>, Dermot Whyms<sup>8</sup>, Chiara Perella<sup>3</sup> and Laura C Coates<sup>9</sup>**

<sup>1</sup>Rheumazentrum Ruhrgebiet Heme, Ruhr-University Bochum, Bochum, Germany; <sup>2</sup>Sorbonne Université, Paris, France; <sup>3</sup>Novartis Pharma AG, Basel, Switzerland; <sup>4</sup>2nd University Hospital, CM UMK, Bydgoszcz, Poland; <sup>5</sup>Hospital Universitario Marqués de Valdecilla, Santander, Spain; <sup>6</sup>Rheumatology Department of Lucania and Rheumatology Institute of Lucania (IRel), San Carlo Hospital of Potenza, Potenza, Italy; <sup>7</sup>University of Erlangen-Nuremberg, Erlangen, Germany; <sup>8</sup>Novartis Ireland Limited, Dublin, Ireland; <sup>9</sup>University of Oxford, Oxford, United Kingdom